Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Aardvark Reports $19.2 Million Third-Quarter Net Loss as FDA Lifts ARD-101 Hold

None

Aardvark Therapeutics (AARD) reported a net loss of $19.2 million, or $0.88 per basic and diluted share, for the third quarter ended September 30, 2026. Research and development expense was $15.7 million, while general and administrative expense was $4.0 million.

The FDA lifted the clinical hold on ARD-101 for hyperphagia in Prader-Willi syndrome in October. Aardvark said it has an FDA meeting scheduled for the first quarter of 2027 and expects to resume PWS clinical activities in 2027, subject to FDA alignment.

  • Cash, cash equivalents and short-term investments totaled $60.3 million as of September 30, 2026.
  • The company said its existing cash resources are expected to fund projected operations through 2027.
  • The FDA agreed Aardvark may conduct an open-label ARD-101 trial at 200 mg twice daily in patients with PWS.
  • The terminated HERO trial randomized 67 of 90 planned participants; the company described efficacy data as exploratory, observational and inconclusive.
  • Aardvark appointed David Zhang, Ph.D., MBA, as an independent director in October 2026.

$AARD Insider Trading Activity

AARD Insider Trades

$AARD insiders have traded $AARD stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $AARD stock by insiders over the last 6 months:

  • NELSON SUN (See Remarks) has made 0 purchases and 2 sales selling 76,754 shares for an estimated $394,957.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS
Receive AARD Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$AARD Hedge Fund Activity

We have seen 22 institutional investors add shares of $AARD stock to their portfolio, and 56 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • BLACKROCK, INC. removed 605,526 shares (-76.4%) from their portfolio in Q2 2026, for an estimated $3,487,829
  • ECOR1 CAPITAL, LLC added 396,194 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,282,077
  • AQR CAPITAL MANAGEMENT LLC added 345,754 shares (+257.1%) to their portfolio in Q2 2026, for an estimated $1,991,543
  • TETRAGON PARTNERS GP LTD removed 316,621 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,823,736
  • RENAISSANCE TECHNOLOGIES LLC removed 70,792 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $407,761
  • NORTHERN TRUST CORP removed 60,519 shares (-68.3%) from their portfolio in Q2 2026, for an estimated $348,589
  • TWO SIGMA INVESTMENTS, LP removed 54,978 shares (-33.7%) from their portfolio in Q2 2026, for an estimated $316,673

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles